5 Best Low Risk Stocks To Buy In 2022

4. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 83

Beta Value: 0.56

Johnson & Johnson (NYSE:JNJ) is an American multinational company operating in the healthcare sector worldwide. On October 20, Johnson & Johnson (NYSE:JNJ)’s Health Care Systems DePuy Synthes was awarded a $244.31 million fixed-price, ID/IQ contract for orthopedic procedural packages and supplies. This is a one-year base contract with four one-year option periods. The ordering period will conclude on October 19, 2023. Johnson & Johnson (NYSE:JNJ) will serve the Army, Navy, Air Force, Marine Corps, and federal civilian agencies. The Defense Logistics Agency initiated the contract. Johnson & Johnson (NYSE:JNJ) is one of the premier low risk stocks to buy in 2022. 

On October 19, Bernstein analyst Lee Hambright maintained a Market Perform rating on Johnson & Johnson (NYSE:JNJ) but lowered the price target on the shares to $190 from $194. The analyst noted that Johnson & Johnson (NYSE:JNJ) announced solid Q3 results as sales grew 8.2% organically to $23.8 billion. Both sales and adjusted EPS beat consensus by 2% despite forex pressures and ongoing macroeconomic challenges, added the analyst, who also highlighted that macro pressures eased somewhat.

According to Insider Monkey’s data, 83 hedge funds were long Johnson & Johnson (NYSE:JNJ) at the end of the second quarter of 2022, and Rajiv Jain’s GQG Partners is the leading position holder in the company, with 6.6 million shares worth $1.16 billion. 

In its Q2 2022 investor letter, Mayar Capital, an asset management firm, highlighted a few stocks and Johnson & Johnson (NYSE:JNJ) was one of them. Here is what the fund said:

“Johnson & Johnson (NYSE:JNJ) is currently our largest position and a long-standing holding. The majority of the group’s sales comes from its collection of pharmaceutical franchises, but a large majority (~45%) comes from its collection of medical device businesses and its consumer brands.

Here’s how JNJ makes and spends a dollar of revenues: As of 2021, about 55 cents of that dollar comes from its pharmaceutical sales – sales of drugs to pharmacies and distributors – while 30 cents come from the sale of medical devices, such as surgery equipment and orthopedics. The rest of that dollar in sales comes from sales of JNJ’s consumer brands such as Listerine mouthwash, Nicorette nicotine tablets and Neutrogena cosmetics (…read more)